Search
Now showing items 1-5 of 5
Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?
(WILEY, 2016-11-01)
PURPOSE: To investigate the effects of different time-resolved angiography with stochastic trajectories (TWIST) k-space undersampling schemes on calculated pharmacokinetic dynamic contrast-enhanced (DCE) vascular parameters. ...
Pre-natal exposures and breast tissue composition: findings from a British pre-birth cohort of young women and a systematic review.
(BMC, 2016-10-12)
BACKGROUND: Breast density, the amount of fibroglandular tissue in the adult breast for a women's age and body mass index, is a strong biomarker of susceptibility to breast cancer, which may, like breast cancer risk itself, ...
A novel approach to evaluate spatial resolution of MRI clinical images for optimization and standardization of breast screening protocols.
(AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS, 2016-12-01)
PURPOSE: Stringent quality assurance is required in MRI breast screening to ensure that different scanners and imaging protocols reach similar diagnostic performance. The authors propose a methodology, based on power ...
Extended T2-IVIM model for correction of TE dependence of pseudo-diffusion volume fraction in clinical diffusion-weighted magnetic resonance imaging.
(IOP PUBLISHING LTD, 2016-12-21)
The bi-exponential intravoxel-incoherent-motion (IVIM) model for diffusion-weighted MRI (DWI) fails to account for differential T 2 s in the model compartments, resulting in overestimation of pseudodiffusion fraction f. ...
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
(RADIOLOGICAL SOC NORTH AMERICA, 2016-07-01)
Purpose To determine the correlation between the volume of bone metastasis as assessed with diffusion-weighted (DW) imaging and established prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) and ...